Drugs / Rabivax-S
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03896724 | May 2019 → Jul 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07147400 | Aug 2025 → Nov 2027 expected | malaria | Serum Institute of India Pvt. Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06066294 | Apr → Nov 2023 | — | Kempegowda Institute of Medical Sciences, Bangalore | Unknown | No outcome recorded |
| Phase 43 trials · 1 missed | ||||||
| Phase 4 | NCT05937113 | Jun → Jul 2020 | rabies | Vietnam Military Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03741270 | Oct 2018 → Mar 2019 | rabies | Ross University School of Veterinary Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03656198 | Aug 2018 → Jul 2020 | diarrheal disease, influenza, upper respiratory tract disorder | Ross University School of Veterinary Medicine | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07183371 Background | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabivax-S | “Safety and immunogenicity of an inactivated vero cell-based rabies vaccine (Rabivax-S) in pre-exposure prophylaxis schedule in Vietnam.” PMID 39927222 ↗ Jan 20257“Participants will be administerd with WHO Pre-qualified rabies vaccine (Rabivax-S)” NCT06066294 ↗ “control vaccine (the Rabivax-S rabies vaccine)” PMID 36087586 ↗ Sep 2022 |
| Modality | Vaccine | “Rabivax-S is a lyophilized vaccine” NCT03656198 ↗ |
| Route | Intramuscular | “via the intramuscular route” NCT03656198 ↗ |